| 1 Leaving the study early |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 1.1 Any reason |
1 |
95 |
Risk Ratio (M‐H, Random, 95% CI) |
0.62 [0.35, 1.10] |
| 1.2 Inefficacy of treatment |
1 |
95 |
Risk Ratio (M‐H, Random, 95% CI) |
0.30 [0.09, 1.04] |
| 2 Global state: Change over time ‐ no better or deterioration |
1 |
95 |
Risk Ratio (M‐H, Random, 95% CI) |
0.43 [0.23, 0.81] |
| 3 Mental state: 1a. General ‐ Less than 20% BPRS reduction |
1 |
95 |
Risk Ratio (M‐H, Random, 95% CI) |
0.7 [0.47, 1.05] |
| 4 Mental state: 1b. General ‐ Less than 30% BPRS reduction |
1 |
95 |
Risk Ratio (M‐H, Random, 95% CI) |
0.82 [0.61, 1.09] |
| 5 Mental state: 1c. General ‐ BPRS endpoint score ‐ per protocol sample (high=poor) |
1 |
79 |
Mean Difference (IV, Random, 95% CI) |
‐6.20 [‐13.20, 0.80] |
| 6 Mental state: 1d. General ‐ BPRS change from baseline to endpoint (high=poor) |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 6.1 per protocol analysis |
1 |
79 |
Mean Difference (IV, Random, 95% CI) |
‐6.1 [‐13.12, 0.92] |
| 6.2 intent‐to‐treat analysis |
1 |
95 |
Mean Difference (IV, Random, 95% CI) |
‐7.10 [‐13.51, ‐0.69] |
| 7 Adverse events: 1. General ‐ at least one adverse event |
1 |
95 |
Risk Ratio (M‐H, Random, 95% CI) |
1.15 [0.87, 1.51] |
| 8 Adverse events: 2. Movement disorder ‐ at least one extrapyramidal side‐effect |
1 |
95 |
Risk Ratio (M‐H, Random, 95% CI) |
13.53 [0.79, 230.37] |
| 9 Adverse events: 3. Movement disorder ‐ use of antiparkinson medication |
1 |
95 |
Risk Ratio (M‐H, Random, 95% CI) |
4.5 [1.04, 19.45] |
| 10 Sensitivity analysis: fixed effects model ‐ global state no better or worse |
1 |
95 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.43 [0.23, 0.81] |
